[EN] SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS<br/>[FR] LACTAMES SPIROCYCLIQUES UTILISÉS COMME INHIBITEURS DU V617F DE JAK2
申请人:[en]INCYTE CORPORATION
公开号:WO2022182839A1
公开(公告)日:2022-09-01
The present application provides spirocyclic lactam compounds of Formula I that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.